Syndax Pharmaceuticals, Inc. (SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia - Slideshow (NASDAQ:SNDX) 2025-10-24 - Reportify

Syndax Pharmaceuticals, Inc. (SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia - Slideshow (NASDAQ:SNDX) 2025-10-24

Syndax(US:SNDX) Seeking Alpha·2025-10-25 06:58

根据提供的文档内容，该文档不包含任何与公司或行业相关的实质性信息无法进行核心观点总结或关键要点分析 [1]